Testosterone Dysregulation and Erectile Dysfunction Associated With Teprotumumab Infusions: A Case Report.
Sri Meghana Konda, Lisa Y Lin, Suzanne K Freitag
✦ AI-curated · Sources linked
Case in brief
A 52-year-old man receiving teprotumumab for active thyroid eye disease developed erectile dysfunction, low libido, and low testosterone during treatment. Testosterone levels and symptoms normalized after the first course. With recurrent eye disease, the same pattern returned during a second course; testosterone replacement improved symptoms and levels, which again normalized after treatment ended. Erectile dysfunction and low testosterone recurred one week after the second dose of a third course, and testosterone replacement again improved his hypogonadal symptoms and levels.
What made this case unusual
The testosterone dysregulation and erectile dysfunction recurred during each of three teprotumumab courses, with testosterone levels normalizing after the first two courses ended.
Diagnostic / clinical pearl
In this case, erectile dysfunction and low testosterone emerged during teprotumumab treatment and recurred with subsequent courses; assessing testosterone may help characterize new hypogonadal symptoms during therapy.